I have noted two failures of targeted medicine this week and now we have additionally one: Torisel!
Pfizer Inc. (NYSE:PFE) said first-line treatment with IV Torisel temsirolimus plus Avastin bevacizumab missed the primary endpoint of improving progression-free survival (PFS) vs. Avastin plus interferon alfa-2a in the Phase III INTORACT trial in 800 advanced renal cell carcinoma patients. Pfizer declined to provide details or next steps, but did say the study outcome does not change the safety and efficacy of single agent Torisel for advanced RCC. Pfizer markets Torisel in the U.S. to treat advanced RCC; the label does not specify a line of treatment. In the EU, Torisel is marketed for first-line treatment of advanced RCC and to treat mantle cell lymphoma (MCL).
Just more money to burn! For sure, Pfizer as a richest Big Pharma company can burn afford the resources!
No comments:
Post a Comment